Ceribell Inc (CBLL) Stock Price, Quote & News

Company Profile

CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates...

Industry: Medical Devices

Sector: Healthcare

Phone: 800 436 0826

Website: www.ceribell.com

Address:

360 North Pastoria Avenue, Sunnyvale, United States

MarketBeat May. 11 at 11:06 PM

https://marketbeat.com/a/8648977/ $CBLL CeriBell Q1 Earnings Call Highlights

0 · Reply

EarningsInsider May. 11 at 9:47 PM

https://www.marketbeat.com/earnings/reports/2026-5-11-ceribell-stock/ $CBLL CeriBell Earnings Transcript

0 · Reply

StocktwitsEarnings May. 11 at 8:23 PM

$CBLL Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.52 down -44.44% YoY • Reported revenue of $26.49M up 29.30% YoY • Ceribell is raising its revenue guidance for the full year 2026 to a range of $112M to $116M, representing growth of approximately 26% to 30% over the company's prior year revenue.

0 · Reply

OfficialStocktwitsUser Apr. 8 at 4:06 PM

$CBLL RSI: 48.76, MACD: -0.2405 Vol: 0.46, MA20: 18.56, MA50: 19.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StocktwitsEarnings Feb. 24 at 9:32 PM

$CBLL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.36 up 10.00% YoY • Reported revenue of $24.78M up 33.72% YoY • Ceribell expects full year 2026 revenue to be between $111M and $115M, representing 25% to 29% growth over the prior year's revenue.

0 · Reply

BillionerOfKing Feb. 21 at 3:54 PM

$CBLL Current Stock Price: $20.20 Contracts to trade: $20.0 CBLL Mar 20 2026 Call Entry: $0.30 Exit: $0.51 ROI: 69% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

TriggerTamer Feb. 18 at 10:04 AM

$CBLL Nano-cap where news scarcity increases risk premium.

1 · Reply

OfficialStocktwitsUser Feb. 13 at 3:14 PM

$CBLL RSI: 38.17, MACD: -0.2449 Vol: 0.93, MA20: 20.96, MA50: 21.24 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

AnalystAdvantage Feb. 4 at 3:36 PM

$CBLL is a fintech or cryptocurrency company; without specifics, it likely operates in a highly speculative and volatile segment.

1 · Reply

OfficialStocktwitsUser Feb. 3 at 8:48 PM

$CBLL RSI: 31.40, MACD: -0.0260 Vol: 1.04, MA20: 21.99, MA50: 20.59 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Ceribell price target lowered to $25 from $28 at Canaccord

2026-05-11T21:24:09.000Z - 1 day ago

Ceribell reports Q1 EPS (52c), consensus (39c)

2026-05-11T21:21:27.000Z - 1 day ago

Ceribell sees FY26 revenue $112M-$116M, consensus $113.18M

May 11, 2026, 4:30 PM EDT - 1 day ago

CeriBell Earnings Call Transcript: Q1 2026

May 11, 2026, 4:05 PM EDT - 1 day ago

Ceribell Reports First Quarter 2026 Financial Results

Apr 29, 2026, 4:05 PM EDT - 13 days ago

Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference

Apr 20, 2026, 4:05 PM EDT - 22 days ago

Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026

2026-04-07T14:58:42.000Z - 5 weeks ago

Ceribell receives 510(k) premarket notification for brain monitor headband

Mar 3, 2026, 1:50 PM EST - 2 months ago

CeriBell Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 4:00 PM EST - 2 months ago

CeriBell Transcript: 47th Annual Raymond James Institutional Investor Conference

2026-02-25T11:53:53.000Z - 2 months ago

Ceribell price target lowered to $28 from $30 at Canaccord

2026-02-24T21:35:58.000Z - 2 months ago

Ceribell reports Q4 EPS (36c), consensus (41c)

2026-02-24T21:35:15.000Z - 2 months ago

Ceribell sees FY26 revenue $111M-$115M, consensus $112.67M

Feb 24, 2026, 4:30 PM EST - 2 months ago

CeriBell Earnings Call Transcript: Q4 2025

Feb 24, 2026, 4:05 PM EST - 2 months ago

Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 18, 2026, 4:05 PM EST - 2 months ago

Ceribell to Participate in Upcoming March Investor Conferences

Feb 10, 2026, 4:05 PM EST - 3 months ago

Ceribell to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Jan 12, 2026, 12:00 PM EST - 4 months ago

CeriBell Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-05T13:10:55.000Z - 4 months ago

Ceribell receives FDA breakthrough device designation for LVO SD monitor

Jan 5, 2026, 8:00 AM EST - 4 months ago

Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution

Dec 30, 2025, 4:05 PM EST - 4 months ago

Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference

2025-12-17T12:20:46.000Z - 5 months ago

Ceribell price target raised to $30 from $29 at Canaccord

2025-12-09T16:10:20.000Z - 5 months ago

Ceribell price target raised to $29 from $20 at TD Cowen

2025-12-09T13:11:41.000Z - 5 months ago

Ceribell receives FDA 510k clearance for delirium screening, monitoring device

Dec 9, 2025, 8:00 AM EST - 5 months ago

Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution

Dec 3, 2025, 9:10 AM EST - 5 months ago

CeriBell Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-02T18:20:25.000Z - 5 months ago

Ceribell management to meet virtually with BTIG

2025-11-24T13:05:47.000Z - 6 months ago

Ceribell receives FDA 510(k) clearance for Clarity algorithm

Nov 24, 2025, 8:00 AM EST - 6 months ago

Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates

Nov 20, 2025, 8:30 AM EST - 6 months ago

CeriBell Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum

Nov 19, 2025, 4:05 PM EST - 6 months ago

Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 4:05 PM EST - 6 months ago

Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

2025-11-05T13:56:03.000Z - 6 months ago

Ceribell price target lowered to $20 from $36 at TD Cowen

2025-11-05T12:45:56.000Z - 6 months ago

Ceribell price target lowered to $17 from $21 at JPMorgan

2025-11-04T22:06:18.000Z - 6 months ago

Ceribell raises FY25 revenue view to $87M-$89M from $85M-$88M

2025-11-04T22:01:05.000Z - 6 months ago

Ceribell reports Q3 EPS (37c), consensus (41c)

Nov 4, 2025, 4:30 PM EST - 6 months ago

CeriBell Earnings Call Transcript: Q3 2025

2025-11-04T21:11:36.000Z - 6 months ago

Ceribell files $300M mixed securities shelf

Nov 4, 2025, 4:05 PM EST - 6 months ago

Ceribell Reports Third Quarter 2025 Financial Results

Oct 21, 2025, 4:05 PM EDT - 7 months ago

Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025

2025-10-20T20:15:20.000Z - 7 months ago

Ceribell initiated with a Strong Buy at Raymond James

2025-09-22T12:25:36.000Z - 8 months ago

Ceribell appoints Erica Rogers to board of directors

Sep 22, 2025, 8:00 AM EDT - 8 months ago

Medtech Leader Erica Rogers Joins Ceribell Board of Directors

Aug 12, 2025, 2:00 PM EDT - 9 months ago

CeriBell Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 5, 2025, 4:30 PM EDT - 10 months ago

CeriBell Earnings Call Transcript: Q2 2025

Aug 5, 2025, 4:05 PM EDT - 10 months ago

Ceribell Reports Second Quarter 2025 Financial Results

Jul 22, 2025, 4:05 PM EDT - 10 months ago

Ceribell to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 7, 2025, 4:42 PM EDT - 11 months ago

Ceribell Files Complaints Against Natus Medical Incorporated with the U.S. International Trade Commission and Federal Court in Delaware

Jun 3, 2025, 10:20 AM EDT - 1 year ago

CeriBell Transcript: 45th Annual William Blair Growth Stock Conference

May 20, 2025, 4:05 PM EDT - 1 year ago

Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference

May 14, 2025, 1:55 PM EDT - 1 year ago

CeriBell Transcript: Bank of America 2025 Healthcare Conference

May 8, 2025, 4:30 PM EDT - 1 year ago

CeriBell Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Ceribell Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems

Apr 24, 2025, 4:05 PM EDT - 1 year ago

Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 15, 2025, 8:00 AM EDT - 1 year ago

FDA Clears Ceribell's Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older

Mar 3, 2025, 9:50 AM EST - 1 year ago

CeriBell Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 4:30 PM EST - 1 year ago

CeriBell Earnings Call Transcript: Q4 2024

Feb 25, 2025, 4:05 PM EST - 1 year ago

Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 18, 2025, 4:05 PM EST - 1 year ago

Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 11, 2025, 4:05 PM EST - 1 year ago

Ceribell to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Jan 13, 2025, 10:30 AM EST - 1 year ago

CeriBell Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 23, 2024, 4:05 PM EST - 1 year ago

Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 12, 2024, 4:30 PM EST - 1 year ago

CeriBell Earnings Call Transcript: Q3 2024

Oct 29, 2024, 4:05 PM EDT - 1 year ago

Ceribell to Report Third Quarter 2024 Financial Results on November 12, 2024

Oct 16, 2024, 4:05 PM EDT - 1 year ago

New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG

Oct 15, 2024, 5:00 PM EDT - 1 year ago

CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 11, 2024, 5:01 PM EDT - 1 year ago

CeriBell IPO: Stock price will be closely watched today as the AI brain-monitoring headband maker debuts on the Nasdaq

Oct 11, 2024, 12:03 PM EDT - 1 year ago

Ceribell's stock indicates up 35% in trading debut after pricing IPO at top of range

Oct 10, 2024, 11:27 PM EDT - 1 year ago

CeriBell, Inc. Announces Pricing of Upsized Initial Public Offering

MarketBeat May. 11 at 11:06 PM

https://marketbeat.com/a/8648977/ $CBLL CeriBell Q1 Earnings Call Highlights

0 · Reply

EarningsInsider May. 11 at 9:47 PM

https://www.marketbeat.com/earnings/reports/2026-5-11-ceribell-stock/ $CBLL CeriBell Earnings Transcript

0 · Reply

StocktwitsEarnings May. 11 at 8:23 PM

0 · Reply

OfficialStocktwitsUser Apr. 8 at 4:06 PM

0 · Reply

StocktwitsEarnings Feb. 24 at 9:32 PM

0 · Reply

BillionerOfKing Feb. 21 at 3:54 PM

0 · Reply

TriggerTamer Feb. 18 at 10:04 AM

$CBLL Nano-cap where news scarcity increases risk premium.

1 · Reply

OfficialStocktwitsUser Feb. 13 at 3:14 PM

0 · Reply

AnalystAdvantage Feb. 4 at 3:36 PM

$CBLL is a fintech or cryptocurrency company; without specifics, it likely operates in a highly speculative and volatile segment.

1 · Reply

OfficialStocktwitsUser Feb. 3 at 8:48 PM

0 · Reply

prismmarketview Jan. 7 at 5:51 PM

Ceribell (NASDAQ: $CBLL) has received FDA Breakthrough Device Designation for its AI‑driven EEG monitor that detects large vessel occlusion (LVO) strokes in hospitalized patients, expanding its point‑of‑care brain monitoring platform beyond seizure and delirium detection and reinforcing EEG as a new vital sign for acute neurology. https://prismmarketview.com/all-eyes-on-ceribell-after-receiving-fda-breakthrough-device-designation/

0 · Reply

ZacksResearch Jan. 6 at 6:34 PM

FDA breakthrough boost for $CBLL! 🚀 Ceribell's LVO stroke detection tech just scored Breakthrough Device Designation, setting the stage for faster FDA interactions and earlier commercialization. This move strengthens its long-term growth outlook by enhancing visibility with hospitals and partners. Discover the full story here 👉 https://www.zacks.com/stock/news/2812871/cbll-wins-fda-breakthrough-status-for-ai-based-lvo-stroke-detection?cid=sm-stocktwits-2-2812871-body-27640&ADID=SYND_STOCKTWITS_TWEET_2_2812871_BODY_27640

0 · Reply

ZacksResearch Jan. 6 at 5:34 PM

$CBLL just scored a major FDA win — and the market might be underestimating it. 🚨 Ceribell earned FDA Breakthrough status for its AI-driven EEG solution designed to detect and monitor LVO strokes in hospitals, a move that boosts clinical credibility and strengthens its growth outlook. See why this regulatory milestone matters for CBLL 👉 https://www.zacks.com/stock/news/2812871/cbll-wins-fda-breakthrough-status-for-ai-based-lvo-stroke-detection?cid=sm-stocktwits-2-2812871-teaser-27637&ADID=SYND_STOCKTWITS_TWEET_2_2812871_TEASER_27637

0 · Reply

topstockalerts Jan. 5 at 2:20 PM

$CBLL look who’s up.. ⬆️

0 · Reply

Avocado_smash Jan. 5 at 2:10 PM

$CBLL

0 · Reply

StockElementCorporation Jan. 5 at 2:08 PM

Premarket Movers 📈 Upside: $GHRS +43% (FDA lifts clinical hold) $CBLL +25% (FDA breakthrough device) $CRNX +19% (Phase 2 update) $ALT +17% (FDA breakthrough therapy) $NMRA +12% (positive Phase 1b, higher-dose plans) MBLY +8.2% (ADAS win, upgrade) LBRT +8.0% (data center power partnership) SLB +7.6% (energy optimism) CVX +6.7% (energy optimism) BKSY +5.7% (defense-related news) PSX +5.3% (refinery asset acquisition) TARA +5.0% (FDA breakthrough + fast track) BBBY +4.9% (new CEO) DUOL +4.2% (upgrade) COIN +4.1% (BTC strength, upgrade) CRWV +3.9% (upgrade) EL +3.7% (upgrade) MRVL +3.5% (upgrade) SPIR +3.5% (defense-related news) KBR +3.3% (government contract) INCY +3.2% (regulatory filing plans) QXO +2.4% (Apollo investment) Downside: ZBIO -46% (Phase 3 data miss)

0 · Reply

Avocado_smash Jan. 5 at 2:07 PM

$CBLL

0 · Reply

ChazzyTrades Jan. 5 at 1:54 PM

$CBLL juicy

1 · Reply

Avocado_smash Jan. 5 at 1:29 PM

$CBLL

0 · Reply

CollateralCap Dec. 26 at 3:33 PM

$CBLL Capital is flowing toward execution strength rather than speculative optionality. Balance sheet resilience remains an underappreciated swing factor. Evidence of repeatability is likely to change market tone. The trajectory strengthens as results compound visibly.

0 · Reply

JarvisFlow Dec. 17 at 7:56 PM

Canaccord Genuity has updated their rating for CeriBell ( $CBLL ) to Buy with a price target of 30.

0 · Reply

Market Cap	759.71M
Revenue (ttm)	89.06M
Net Income (ttm)	-53.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-59.97%
Debt to Equity Ratio	0.13

Volume	1,167,400
Avg Vol	289,772
Day's Range	N/A - N/A
Shares Out	37.87M
Stochastic %K	14%
Beta	0.99
Analysts	Strong Sell
Price Target	$27.57